TrialInternational journal of hematology2017
Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.
Sohsuke Meshitsuka et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it